MTOR and gastric cancer: Our analysis of the cytarabine‐docetaxel combination revealed significant enrichment in the mTOR signaling pathway (P‐value = 6.64 × 10−9) and Ras signaling pathway (P‐value = 6.89 × 10−9), suggesting synergy through the simultaneous targeting of key cancer pathways involved in tumor growth and survival in gastric cancer.